SMN2 and proximal spinal muscular atrophy: Screening is conducted using DNA extracted from dried blood spots with a multiplex real-time quantitative polymerase chain reaction assay targeting SMN1 exon 7 which can be differentiated from SMN2 exon 7 and is deleted in 95% of SMA patients [29].